Results 151 to 160 of about 99,037 (313)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Development of detection kit for anti-platelet antibodies in patients with thrombocytopenia by modified SPRCA

Journal of Associated Medical Sciences, 2008
Detection of anti-platelet alloantibodies in serum of patients with thrombocytopenia is important for helps in diagnosis and investigation as well as specific treatment. Since, platelets provide both common and platelet specific antigens which can induce
Witoon Sriwichai, Jaturaporn Pornsinlapatip, Preeyanat Vongchan   +2 more
doaj  

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

Advanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim, Loganayaki Periyasamy, Natarajan Aravindan   +7 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Microglial GPR35 Ameliorates Epileptogenesis and Neuroinflammation via PDGFA Domain 2 Signaling

Advanced Science, EarlyView.
Activation of microglial G protein–coupled receptor 35 (GPR35) by L‐kynurenic acid (L‐Kyna) initiates a platelet‐derived growth factor A (PDGFA)–dependent phosphoinositide 3‐kinase–protein kinase B (PI3K–AKT) signaling cascade that dampens hippocampal neuroinflammation, thereby restraining epileptogenesis, lowering seizure susceptibility, and ...
Qi Wang, Tingting Qu, Qibing Sun, Ran Li, Junfei Dong, Yuming Du, Ziyin Xuan, Lei Wang, Hanli Li, Jianyun Sun, Fangliang Chen, Jinshuai Liu, Zifan Yang, Jianxiang Lei, Qian Yang, Bin Wang, Zhiming Zhou, Yu Wang   +17 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Marked platelet transfusion refractoriness caused by anti-HLA-I and anti-HPA-5b antibodies: A case report. [PDF]

Medicine (Baltimore)
Wang Y, Liu Z, Duan S, Lin C, Jin Y, Wang H, Wang Y, Tang L, Wang M.   +8 more
europepmc   +1 more source

A Subset of Pro‐inflammatory CXCL10+ LILRB2+ Macrophages Derives From Recipient Monocytes and Drives Renal Allograft Rejection

Advanced Science, EarlyView.
This study uncovers a recipient‐derived monocyte‐to‐macrophage trajectory that drives inflammation during kidney transplant rejection. Using over 150 000 single‐cell profiles and more than 850 biopsies, the authors identify CXCL10+ macrophages as key predictors of graft loss.
Alexis Varin, Jovanne Palvair, Lennie Messager, Jamal Bamoulid, Jasper Callemeyn, Mélanie Chaintreuil, Ludivine Dal Zuffo, Didier Ducloux, Imane Farhat, Mathieu Legendre, Laurent Martin, Florian Renosi, Xavier Roussel, Thibaut Vaulet, Maarten Naesens, Claire Tinel, Baptiste Lamarthée   +16 more
wiley   +1 more source

A Diagnostic Challenge: Post-Transfusion Purpura Unmasked After Multiple Transfusions. [PDF]

Clin Case Rep
Thomas J, Gopalan P, Wildes TM.
europepmc   +1 more source

The nature of antiplatelet activity in antilymphoblast ALG--with special reference to cross-reacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients. [PDF]

, 1972
Amemiya, H, Putnam, CW, Starzl, TE, Torisu, M, Yokoyama, T   +4 more
core